Date	e: 7/3/2022		
	r Name:Jillian Gunthe		
			ded study evaluating the efficacy of curcumin with pre-
	rative chemoradiation for re		
Mar	nuscript number (if known):		
rela part to ti	ted to the content of your n ies whose interests may be ransparency and does not no	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a
rela	tionship/activity/interest, it	is preferable that you do	so.
	following questions apply touscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to tl		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	-	d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	x_None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
	no time illine for tims item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	None	RSNA Education Scholars Grant
	any entity (if not indicated		
			I I
	in item #1 above).		
3		x_None	

Consulting fees

Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events				
testimony Support for attending meetings and/or travel Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services 3 Other financial or non- Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Leadership or fiduciary role in other services Lead	5	lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
Meetings and/or travel	6	The state of the s	xNone	
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services None Executive Board Member of ROECSG Vice Chair Education Committee of ILROG X None X None X None A None A None Total Committee of ILROG A None A None Total Committee of ILROG Total Committee o	7		_xNone	
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- Stock or stock options Leadership or fiduciary role in None Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Leadership or fiduciary role in None Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Leadership or fiduciary role in None Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Leadership or fiduciary role in One in None Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Executive Board Member of ROECSG Executive Board Member of ROECSG Vice Chair Education Committee of ILROG Executive Board Member of ROECSG E	8	T	xNone	
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options x_None	9	Safety Monitoring Board or	x_None	
11 Stock or stock options x_None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or nonx_None x_None	10	in other board, society, committee or advocacy	None	
materials, drugs, medical writing, gifts or other services 13 Other financial or nonxNone	11		xNone	
	12	materials, drugs, medical writing, gifts or other	xNone	
	13		xNone	

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e:7	//3/2022		
You	r Name:	Awalpreet S. (Chadha	
Man	uscript Title	e: A phase I	I randomized double bline	ded study evaluating the efficacy of curcumin with pre-
ope	rative chem	oradiation for re	ectal cancer	
Man	nuscript num	nber (if known):		
relat part to tr	ted to the co ies whose ir ansparency	ontent of your materests may be and does not no	nanuscript. "Related" mea affected by the content o	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following quuscript only		o the author's relationshi	os/activities/interests as they relate to the current
to th	ne epidemio	logy of hyperter		defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
			port for the work reported the past 36 months.	d in this manuscript without time limit. For all other items,
			Name all entities with	Specifications/Comments
			whom you have this	(e.g., if payments were made to you or to your
			relationship or indicate	institution)
			none (add rows as	,
			needed)	
			Time frame: Since the initia	al planning of the work
1	All support f	or the present	xNone	
	manuscript	(e.g., funding,		
	provision of	study materials,		
	medical writ	ing, article		
	processing c	harges, etc.)		
	No time lim	it for this item.		
			Time frame: pas	t 36 months
2	Grants or co	ntracts from		t 30 months
_			xNone	
		f not indicated		
	in item #1 al			
3	Royalties or	licenses	xNone	

4

Consulting fees

5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e: 7/3/2022		
	r Name:Sushovan Gul	na	
Mar	nuscript Title: A phase	II randomized double blin	ded study evaluating the efficacy of curcumin with pre-
ope	rative chemoradiation for re	ectal cancer	
Mar	nuscript number (if known):		
relate part to trelate man. The to the med. In it.	ted to the content of your raises whose interests may be ransparency and does not notionship/activity/interest, in following questions apply the suscript only. author's relationships/activity author's relationships/activity endemiology of hypertelication, even if that medical	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. It is preferable that you do to the author's relationshit wities/interests should be nsion, you should declare ation is not mentioned in the port for the work reporte	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed) Time frame: Since the initi	ol planning of the work
1	All account for the consequent		al planning of the work
1	All support for the present manuscript (e.g., funding,	xNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
2	Grants or contracts from	xNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	x None	

4

Consulting fees

5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Dat	e: //3/2022		
You	ır Name:Gottumukkala	a S. Raju	
Ma	nuscript Title: A phase I	II randomized double blind	ded study evaluating the efficacy of curcumin with pre-
ope	rative chemoradiation for re	ectal cancer	
Ma	nuscript number (if known):		
rela par to t	ited to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to t		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	tem #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	x_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	1		
2		Time frame: nas	t 36 months
_	Grants or contracts from	Time frame: pas	t 36 months
	Grants or contracts from any entity (if not indicated	Time frame: pas	t 36 months
	any entity (if not indicated		t 36 months
3	any entity (if not indicated in item #1 above).		t 36 months
3	any entity (if not indicated	xNone	t 36 months

Consulting fees

5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e:7/	3/2022		
You	r Name:	Dipen Maru		
				nded study evaluating the efficacy of curcumin with pre-
-			ectal cancer	
Mar	nuscript numb	er (if known):		
rela part to ti	ted to the con ies whose into ransparency a	tent of your nerests may be not	nanuscript. "Related" me affected by the content	I relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment. If you are in doubt about whether to list a poso.
	following que	stions apply to	o the author's relationsh	ips/activities/interests as they relate to the current
to tl	he epidemiolo	gy of hyperte		defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
			port for the work reporte the past 36 months.	ed in this manuscript without time limit. For all other items,
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the init	ial planning of the work
1	All support for manuscript (e. provision of st medical writin processing characteristics).	g., funding, udy materials, g, article arges, etc.)	xNone	
			Time from	st 26 months
2	Grants or cont	racts from	Time frame: pa x None	St 50 months
	any entity (if n in item #1 abo	ot indicated		
3	Royalties or lic	censes	xNone	

Consulting fees

5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e: 7/3/2022		
You	r Name:Mark Munsel	l	
Man	uscript Title: A phase	II randomized double blind	ed study evaluating the efficacy of curcumin with pre-
ope	rative chemoradiation for r	ectal cancer	
Man	uscript number (if known):		
relat part to tr	ted to the content of your r ies whose interests may be	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so.
	following questions apply t uscript only.	o the author's relationship	s/activities/interests as they relate to the current
to th		nsion, you should declare	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.
	em #1 below, report all sup time frame for disclosure is	•	l in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present	x_None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time illustroi tius item.		
		T:	2C months
2	Grants or contracts from	Time frame: past	. So months
2	Grants or contracts from	x_None	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	xNone	
5	Noyalties of ficerises	^NOTIC	

Consulting fees

5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e:7/3/2022_		
Your	r Name:Yan Jian	g	
Man	nuscript Title: A ph	hase II randomized double	e blinded study evaluating the efficacy of curcumin with pre-
oper	rative chemoradiation	for rectal cancer	
Man	nuscript number (if kno	own):	
relate to trelate to trelate the man to the med	ted to the content of y ies whose interests may an ansparency and does it tionship/activity/interestionship/activity/interestionship questions appropriate the content of t	your manuscript. "Related ay be affected by the cont not necessarily indicate a rest, it is preferable that you pply to the author's relation activities/interests should pertension, you should depended in the control of the control	onships/activities/interests as they relate to the <u>current</u> Id be <u>defined broadly</u> . For example, if your manuscript pertains eclare all relationships with manufacturers of antihypertensive ed in the manuscript.
	· •	II support for the work repure is the past 36 months.	ported in this manuscript without time limit. For all other items,
		Name all entities wit	h Specifications/Comments
		whom you have this	
		relationship or indica	
		none (add rows as	
		needed)	
		Time frame: Since th	e initial planning of the work
1	All support for the prese		
	manuscript (e.g., fundin		
	provision of study mate	rials,	
	medical writing, article	,	
	processing charges, etc. No time limit for this ite		
	NO time initial for tims ite	=======================================	
		Timo fram	e: past 36 months
2	Grants or contracts from		e. past 30 months
-	any entity (if not indicat		
	in item #1 above).		
3	Royalties or licenses	x None	
	,		

Consulting fees

5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e: 7/3	/2022		
You	r Name:P	eiying Yang		
				ded study evaluating the efficacy of curcumin with pre-
-			ectal cancer	
Man	uscript numbe	r (if known):		
relate part to trelate The	ted to the conto ies whose inter ransparency and tionship/activit	ent of your mests may be does not not sy/interest, it	nanuscript. "Related" me affected by the content o ecessarily indicate a bias. is preferable that you do	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the manuscript of the manuscript. Disclosure represents a commitment of the manuscript. Dis
to th	ne epidemiolog lication, even if	y of hyperter that medica	nsion, you should declare tion is not mentioned in	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. ed in this manuscript without time limit. For all other items,
			the past 36 months.	
			Name all entities with	Specifications/Comments
			whom you have this	(e.g., if payments were made to you or to your
			relationship or indicate	institution)
			none (add rows as	
			needed)	
			Time frame: Since the init	all planning of the work
1	All support for t	•	xNone	_
	manuscript (e.g provision of students	_		
	medical writing	-		
	processing char			
	No time limit fo			
			Time frame: pa	st 36 months
2	Grants or contra	acts from	x None	
	any entity (if no			
	in item #1 above			
3	Royalties or lice	nses	xNone	

4

Consulting fees

5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e:7/3/2022		
	Name:Edd Felix		
			ded study evaluating the efficacy of curcumin with pre-
-	rative chemoradiation for r		
Man	uscript number (if known)		
relate partito trelate The man The to the med	ted to the content of your raies whose interests may be ansparency and does not notionship/activity/interest, if following questions apply touscript only. author's relationships/activity e epidemiology of hyperterication, even if that medical	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. It is preferable that you do to the author's relationship wities/interests should be nsion, you should declare ation is not mentioned in the	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
2		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	x None	
	•		

Consulting fees

5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e:		
You	r Name:Marilyn Clem	ons	
Mar	nuscript Title: A phase I	II randomized double blind	ded study evaluating the efficacy of curcumin with pre-
ope	rative chemoradiation for re	ectal cancer	
Mar	nuscript number (if known):		
rela part to t	ted to the content of your nies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to t	ne epidemiology of hyperter lication, even if that medica	nsion, you should declare ation is not mentioned in t	·
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed) Time frame: Since the initia	al planning of the work
1	All support for the present	x None	a planning of the work
1	manuscript (e.g., funding,	x_None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	xNone	
	any entity (if not indicated		
3	in item #1 above). Royalties or licenses	x None	
3	Noyalties of ficelises	xNone	

Consulting fees

5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e:7/3/2022		
You	r Name:Geena George	e Mathew	
Man	nuscript Title: A phase I	I randomized double bline	ded study evaluating the efficacy of curcumin with pre-
•	rative chemoradiation for re		
Man	nuscript number (if known):		
relate to trelate man The man The to the med In ite	ted to the content of your name ies whose interests may be cansparency and does not not interest, in following questions apply the content only. author's relationships/actions e epidemiology of hyperte lication, even if that medical	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. It is preferable that you do to the author's relationship vities/interests should be p nsion, you should declare ation is not mentioned in t	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
2		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	x None	
	•		

Consulting fees

5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e:7/3/2	.022		
You	r Name:Par	nkaj Singh		
				led study evaluating the efficacy of curcumin with pre-
-			ctal cancer	
Mar	nuscript number (if known):_		
rela part to ti	ted to the contenties whose interestransparency and o	t of your m sts may be a does not ne	anuscript. "Related" mea	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third if the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questicnuscript only.	ons apply to	the author's relationship	os/activities/interests as they relate to the <u>current</u>
to the med	he epidemiology o dication, even if th em #1 below, rep	of hyperter hat medicat oort all supp	sion, you should declare tion is not mentioned in t	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript. If in this manuscript without time limit. For all other items,
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
			Time frame: Since the initia	l planning of the work
1	All support for the	present	xNone	
	manuscript (e.g., f	_		
	provision of study			
	medical writing, a processing charge			
	No time limit for t			
				+
			Time frame: pas	t 36 months
2	Grants or contract any entity (if not i		xNone	

in item #1 above).

Royalties or licenses

Consulting fees

4

_x__None

5	Payment or honoraria for	xNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:7/3/2022
Your Name:John Skibber
Manuscript Title: A phase II randomized double blinded study evaluating the efficacy of curcumin with pre-
operative chemoradiation for rectal cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	x_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	xNone	
4	Consulting fees	xNone	

5	Payment or honoraria for lectures, presentations,	xNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e:		
You	r Name:Miguel Rodrig	guez-Bigas	
Mar	nuscript Title: A phase I	II randomized double blind	ded study evaluating the efficacy of curcumin with pre-
ope	rative chemoradiation for re	ectal cancer	
Mar	nuscript number (if known):		
rela part to t	ted to the content of your n ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to ti med In it	he epidemiology of hypertendication, even if that medication	nsion, you should declare ation is not mentioned in to port for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript. d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate	(e.g., if payments were made to you or to your institution)
		none (add rows as needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	x None	n planning of the work
1	manuscript (e.g., funding,	x_None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	xNone	
	any entity (if not indicated		<u> </u>
3	in item #1 above). Royalties or licenses	x None	
3	Noyalties of ficelises	xNone	

Consulting fees

5	Payment or honoraria for lectures, presentations,	xNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:7/3/2022
Your Name:George Chang
Manuscript Title: A phase II randomized double blinded study evaluating the efficacy of curcumin with pre- operative chemoradiation for rectal cancer
Manuscript number (if known):
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> .
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertain to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other item

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	xNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	xNone	
3	Royalties or licenses	x_None	
4	Consulting fees	xNone	

5	Payment or honoraria for lectures, presentations,	xNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e: 7/3/2022		
You	r Name:Cathy Eng		
Man	nuscript Title: A phase	II randomized double bline	ded study evaluating the efficacy of curcumin with pre-
ope	rative chemoradiation for I	rectal cancer	
Mar	nuscript number (if known)	:	
relat part to tr relat	ted to the content of your lies whose interests may be ransparency and does not i tionship/activity/interest,	manuscript. "Related" mea e affected by the content o necessarily indicate a bias. it is preferable that you do	
	following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to the med	ne epidemiology of hyperto lication, even if that medic	ension, you should declare ation is not mentioned in toport for the work reported	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	x_None	
	processing charges, etc.) No time limit for this item.		
	time mine for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	xNone	
	any entity (if not indicated		
2	in item #1 above).	y None	
3	Royalties or licenses	x_None	

Consulting fees

5	Payment or honoraria for lectures, presentations,	xNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e: 7/3/2022		
You	r Name:Marc Delclos		
			ded study evaluating the efficacy of curcumin with pre-
-	rative chemoradiation for re		
Mar	nuscript number (if known):		
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply t nuscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to tl		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	al manning of the work
1	All account for the property	Time frame: Since the initia	ai planning of the work
1	All support for the present manuscript (e.g., funding,	xNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
2	Cuanta au contra de france	Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated	xNone	
	in item #1 above).		+
3	Royalties or licenses	x None	
	. ,		

Consulting fees

5	Payment or honoraria for lectures, presentations,	xNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	xNone	
	testimony		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	x_None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	xNone	
12	Descipt of agricument	y Nege	
12	Receipt of equipment, materials, drugs, medical	xNone	
	writing, gifts or other		
	services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date:7/3/2022
Your Name:Christopher Crane
Manuscript Title: A phase II randomized double blinded study evaluating the efficacy of curcumin with pre-
operative chemoradiation for rectal cancer
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	xNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	xNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	xNone	
4	Consulting fees	xNone	

5	Payment or honoraria for lectures, presentations,	xNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	x_None	
	testimony		
	-		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	xNone	
42			
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e: 7/3/2022		
You	r Name:Prajnan Das		
			ded study evaluating the efficacy of curcumin with pre-
-		rectal cancer	
Mar	nuscript number (if known)	·	
rela part to ti	ted to the content of your lies whose interests may be ransparency and does not i	manuscript. "Related" mea e affected by the content o	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply nuscript only.	to the author's relationship	os/activities/interests as they relate to the <u>current</u>
to tl	he epidemiology of hyperte		defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	em #1 below, report all sup time frame for disclosure is	· •	d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	xNone	
	processing charges, etc.) No time limit for this item.		
	No time initiation this itemi		
		Time frame: pas	t 36 months
2	Grants or contracts from	x None	
	any entity (if not indicated		

in item #1 above).
Royalties or licenses

Consulting fees

4

_x__None

5	Payment or honoraria for lectures, presentations,	xNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	x_None	
	testimony		
	-		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	xNone	
42			
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date	e: 7/3/2022		
	r Name:Sunil Krishnar	1	
Mar	nuscript Title: A phase I	I randomized double blin	ded study evaluating the efficacy of curcumin with pre-
ope	rative chemoradiation for re	ectal cancer	
Mar	nuscript number (if known):		
relar part to to to relar. The man to	ted to the content of your name ites whose interests may be ransparency and does not not item in the content of your name items in the your name items in the content of your name items in the your name items	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. It is preferable that you do to the author's relationshit vities/interests should be nsion, you should declare ation is not mentioned in the	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
	time name for disclosure is	the past so months.	
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate none (add rows as	institution)
		needed)	
		Time frame: Since the initi	al planning of the work
1	All support for the present	xNone	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	xNone	
	any entity (if not indicated		
	in item #1 above).		
7	Royalties or licenses	x None	

4

Consulting fees

5	Payment or honoraria for lectures, presentations,	xNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	x_None	
	testimony		
	-		
7	Support for attending meetings and/or travel	_xNone	
8	Patents planned, issued or	xNone	
	pending		
9	Participation on a Data	xNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	xNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	xNone	
42			
12	Receipt of equipment,	xNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	xNone	
	financial interests		

__x_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.